In a post-hoc analysis, Abrocitinib monotherapy at both 100 mg and 200 mg doses illustrated superior effectiveness in various clinical and patient-reported measures compared to placebo in patients suffering from atopic dermatitis (AD). This positive outcome was consistent across different racial groups and a range of Fitzpatrick Skin Types (FST) that were studied. Researchers evaluated the safety and efficiency of Abrocitinib monotherapy for AD management.

Data from volunteers treated with Abrocitinib 200 mg, 100 mg, or placebo in three monotherapy  assessments were retrospectively analyzed. Participants self-reported their ethnicity and race. The investigators examined FST. Assessments up to Week 12 included: (a) At least 75% betterment in Eczema Area and Severity Index (EASI) or SCORing AD; (b) Investigator's Global Assessment (IGA) of clear or almost-clear skin; (c) A four-point or more enhancement in Peak Pruritus Numerical Rating Scale (NRS) score; (d) Least squares mean alteration in Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure scores; and (e) Occurrence of therapy-emergent adverse events.

The overall study consisted of  628 White, 204 Asian, and 83 Black people, 37 of whom were identified as Hispanic or Latino. Furthermore, stratification of the group based on  FST revealed that 624 had FST I to III and 320 had FST IV to VI. After 12 weeks of drug administration, Abrocitinib showed remarkable effectiveness at both doses. Patients treated with either dose of Abrocitinib showed higher percentages of individuals attaining clear or almost-clear skin based on the IGA, as well as attaining a 75% or greater improvement in both the EASI and SCORing AD.

Additionally, there was a notable betterment of four points or more in the Peak Pruritus NRS. Changes in scores from baseline for DLQI and Patient-Oriented Eczema Measure were also more pronounced compared to those receiving a placebo. These positive outcomes were witnessed irrespective of the patient's race, ethnicity, or FST. The dose-response association was highest in White patients. For Black patients, the effects of the two doses were similar. Asian patients experienced fewer adverse events during therapy than White and Black patients did.

The results of this study represent advancements in the management of AD, demonstrating the potential of Abrocitinib to effectively treat the ailment across racial and ethnic subpopulations.